Full-dose GLP-1 medications cause dramatic weight loss — and significant side effects. Microdosing is emerging as a different approach: modest metabolic benefits with fewer side effects. Here's what we know.
The GLP-1 conversation has been dominated by the headline: dramatic weight loss results from full therapeutic doses of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Up to 15–22% body weight reduction in clinical trials. Numbers that weren't previously achievable with any non-surgical intervention.
But full-dose GLP-1 therapy also comes with significant side effects — nausea, vomiting, gastroparesis, constipation, diarrhea, and muscle mass loss — that lead a substantial portion of patients to reduce doses, pause, or discontinue therapy. And for people who don't need or want 15–22% weight loss, the full dose may be more than necessary.
Enter microdosing: using GLP-1 medications at doses well below the standard therapeutic range to achieve moderate metabolic benefits while significantly reducing side effect burden.
What Microdosing Actually Means
There's no universal definition of GLP-1 microdosing, but clinically it generally refers to doses that are 10–30% of the standard approved therapeutic dose. For compounded semaglutide, this might mean 0.1–0.25 mg weekly instead of the standard starting dose of 0.25 mg (which itself titrates up to 2.4 mg for weight management).
At these lower doses, the mechanism of action is the same — GLP-1 receptor agonism — but the magnitude of effect on gastric emptying and appetite suppression is more subtle.
What the Evidence Shows
Dedicated clinical trials on GLP-1 microdosing are limited — most of the research infrastructure has been built around full therapeutic doses for weight management and type 2 diabetes. But several lines of evidence are relevant:
- Dose-response curves for GLP-1 agonists are not linear — meaningful metabolic benefits occur at doses well below those needed for maximal weight loss
- Clinical titration protocols show that many patients see significant improvement in appetite, glucose control, and weight at starting doses (0.25 mg semaglutide) before titrating further
- Real-world data from patients who dose-reduce due to side effects often show sustained metabolic benefit at lower doses
- GLP-1 receptors in the liver, pancreas, and cardiovascular system respond to lower doses than those needed for maximal CNS satiety effects
Who Microdosing May Be Appropriate For
GLP-1 microdosing isn't appropriate for everyone — and it's not a workaround for avoiding lifestyle changes. Potential candidates:
- People with mild metabolic dysfunction (early insulin resistance, pre-prediabetes) who want to address it before it progresses
- People who can't tolerate full-dose GLP-1 therapy due to side effects but want to retain some benefit
- People pursuing a comprehensive lifestyle-based program who want modest pharmacological support
- People who have achieved their weight loss goal at full dose and want to maintain at a lower maintenance dose
The Muscle Mass Question
One of the most significant concerns with full-dose GLP-1 therapy is the loss of lean muscle mass. Studies have shown that 25–40% of total weight lost on GLP-1 medications can be lean mass rather than fat, particularly without concurrent resistance training. This is a real concern because muscle mass loss has long-term consequences for metabolism, strength, and longevity.
Microdosing may attenuate this effect for a simple reason: if appetite suppression is less severe, dietary protein intake remains higher, and the caloric deficit is less extreme. Combining any dose of GLP-1 medication with resistance training and adequate protein intake (1.6–2.2 g per kg of body weight) is essential for preserving lean mass.
What Microdosing Won't Do
Microdosing GLP-1 is not a path to dramatic weight loss. It's not a substitute for addressing sleep, stress, nutrition, and movement. At low doses, the appetite suppression effects are modest, and the weight loss will be modest — if weight loss is the primary goal, full therapeutic doses are more appropriate for most patients with obesity.
The clinical context
Compounded GLP-1 medications are not FDA-approved. They should only be used under the supervision of a licensed clinician who can assess appropriateness, monitor response, and adjust or discontinue based on your individual health status.
The Right Framework
The most effective approach to GLP-1 therapy at any dose is one that treats the medication as a metabolic tool — not a permanent solution. A well-designed program combines the medication with structured nutrition, resistance training, sleep optimization, and regular lab monitoring, with the goal of improving underlying metabolic function so that dependence on the medication decreases over time.